---
title: "Bone Biologics Raises $2.7 Million in Private Placement; Adds $6 Million Upside From Warrants"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292240801.md"
description: "Bone Biologics raised $2.7 million via a private placement of pre-funded warrants and Series F/G common stock warrants at $1.419 per unit, closing July 9, 2026. The deal includes potential additional gross proceeds of ~$6 million upon exercise of common warrants. H.C. Wainwright served as exclusive placement agent. Proceeds will fund trials and working capital."
datetime: "2026-07-09T20:33:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292240801.md)
  - [en](https://longbridge.com/en/news/292240801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292240801.md)
generator: "portal-rs"
---

# Bone Biologics Raises $2.7 Million in Private Placement; Adds $6 Million Upside From Warrants

Bone Biologics completed a privately negotiated financing, selling 2,112,677 pre-funded warrants alongside equal numbers of Series F and Series G common stock warrants at a combined $1.419 per unit. The deal closed on July 9, 2026, generating approximately $2.7 million in net proceeds, with a further ~$6 million in potential gross proceeds if the common warrants are exercised for cash. Series F and G warrants are priced at $1.42 per share and become exercisable following shareholder approval and the effectiveness of a resale registration statement, while pre-funded warrants are immediately exercisable at $0.001 per share. H.C. Wainwright served as exclusive placement agent, receiving customary cash fees, expense reimbursements, and placement agent warrants.

**Agreement 1: Bone Biologics Raises $2.7 Million in Private Placement; Adds $6 Million Upside From Warrants**

-   **Agreement type**: Securities Purchase Agreement for private placement of pre-funded and common warrants
-   **Counterparty**: Investor
-   **Signed / Effective**: Jul 07 2026 / Jul 09 2026
-   **Duration / Termination**: At will
-   **Reason**: Raise capital for trials and working capital

**Agreement 2: Bone Biologics Enters Registration Rights Agreement to Register Resale of Warrant Shares**

-   **Agreement type**: Registration Rights Agreement for resale registration
-   **Counterparty**: Investor
-   **Signed / Effective**: Jul 07 2026 / Jul 07 2026
-   **Duration / Termination**: At will
-   **Reason**: Enable resale liquidity for offering securities

**Agreement 3: Bone Biologics Engages H.C. Wainwright as Placement Agent for July 2026 Offering**

-   **Agreement type**: Exclusive placement agency engagement for private offering
-   **Counterparty**: H.C. Wainwright & Co.
-   **Signed / Effective**: Jul 07 2026 / Jul 09 2026
-   **Duration / Termination**: At will
-   **Reason**: Arrange and place the private financing

Original SEC Filing: Bone Biologics Corp \[ BBLG \] - 8-K - Jul. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBLG.US](https://longbridge.com/en/quote/BBLG.US.md)
- [BBLGW.US](https://longbridge.com/en/quote/BBLGW.US.md)

## Related News & Research

- [ReNew Energy Global warrants set to be delisted after expiration](https://longbridge.com/en/news/296360098.md)
- [REG - Sareum Holdings PLC - Exercise of Warrants](https://longbridge.com/en/news/296362927.md)
- [REG - Neoterra Group PLC - Extension of 2p Warrants to 9 October 2026](https://longbridge.com/en/news/296512113.md)
- [ReconAfrica receives $4.97 million from warrant exercises](https://longbridge.com/en/news/296156008.md)
- [Dogness issues 3,050,000 Class A shares after cash warrant exercise](https://longbridge.com/en/news/296088837.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**